Startups Elucidata and Auron Therapeutics signed a four-year deal to apply multi-omic data analytics for differentiation-based cancer therapies.
The researchers found that tumors expressing STAG2 as a biomarker are twice as likely to recur and progress toward muscle invasion and metastasis.
The agreement grants MDxHealth the rights to manufacture and market the phosphodiesterase-4D7 biomarker as a prognostic test.
The five-year award will provide funding for researchers to investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
The study, called Panfam-1, will analyze 1,000 individuals at high risk of familial pancreatic cancer over three years using the company's antibody array test.
The partners will evaluate new biomarkers that they both find, and will assess the possibility for a preterm birth prognostic panel.
Caris Life Sciences also found that time-to-next treatment could be a surrogate endpoint for survival.
The researchers were able to differentiate among patients with lung cancer, COPD, and health controls using the biomarkers.
Fresh off of a $15 million private placement and restructuring transaction intended to simplify its capital structure, WaferGen Biosystems has shifted its focus to position itself as a provider of tools to supplement next-generation sequencing.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.